Posters
Refractive outcome with posterior chamber copolymer phakic intraocular lens with peripheral hole in moderate to high myopia: single surgeon series
Poster Details
First Author: P.Subudhi INDIA
Co Author(s): S. Patro B. Subudhi
Abstract Details
Purpose:
The purpose of this study is to show safety and efficacy of posterior chamber co polymer phakic intraocular lens (IPCL) with peripheral optic hole for moderate to high myopia in Indian patients.
Setting:
Setting: Ruby Eye Hospital
Methods:
Retrospective analysis of 52 eyes of 32 patients was performed. All patients were assessed as per institute's standard refractive surgery protocol. Patients with clinical keratoconus, glaucoma, metabolic syndromes, macular pathology, retinitis pigmentosa and anterior chamber depth of <3.0 mm were excluded from the study. Preoperative parameters measured were subjective refraction, anterior chamber depth using pentacam and white to white diameter manually by digital callipers.Custom made IPCL using above parameters was implanted in sulcus for correction of moderate to high myopia. All patients underwent Nd:YAG peripheral iridotomy.
Results:
Clinical outcome data were collated retrospectively from the medical case records. Mean age group was 25.41 years ( SD 3.75).55.55% were male recipients. Mean preoperative Best corrected visual acuity (BCVA) was 0.50 logmar units (SD: 0.20, Max: 0.0 and min : 0.9). Post IPCL implantation mean uncorrected visual acuity was 0.29 logmar units (SD: 0.18, Max: 0 and Min: 0.7) with p value >0.05 compared to pre-op BCVA. 24 patients (75% % ; Satisfaction score [1-5] - >/= 4) cases were very satisfied to extremely satisfied. Rest of the patients were optimally satisfied.
Conclusions:
Posterior chamber co polymer phakic intraocular lens with peripheral hole resulted in clinically significant improvement of unaided visual acuity. Long term follow up showed optimum stability of vision . None of the patients had anterior sub-capsular cataract, angle closure glaucoma and lens decentration during the follow up period.
Financial Disclosure:
NONE
